XILIO THERAPEUTICS INC (XLO) Stock News

USA - Nasdaq - NASDAQ:XLO - US98422T1007 - Common Stock

0.7302 USD

-0.01 (-1.46%)

Last: 12/5/2025, 8:00:02 PM

0.72 USD

-0.01 (-1.4%)

After Hours: 12/5/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

XLO Latest News, Press Relases and Analysis

All

Press Releases

25 days ago - By: Zacks Investment Research - Mentions: IMTX

Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

25 days ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

25 days ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

26 days ago - By: Zacks Investment Research - Mentions: BTAI

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates

a month ago - By: Benzinga - Mentions: SGMO NNVC REVB CYCN ...

12 Health Care Stocks Moving In Monday's After-Market Session

3 months ago - By: Stocktwits - Mentions: GILD

News Image

Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued

a month ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

a month ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

a month ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

a month ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

a month ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

a month ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

2 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

2 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

2 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

3 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

4 months ago - By: Zacks Investment Research - Mentions: MGTX

Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: The Motley Fool - Mentions: GILD

Xilio Revenue Jumps 246 Percent in Q2

4 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

4 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

4 months ago - By: Yahoo Finance - Mentions: WFC UBS MNDY CACI ...

Snap downgraded, Leidos upgraded: Wall Street's top analyst calls

4 months ago - By: Catalyst Pharmaceuticals, Inc. - Mentions: CPRX

Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

4 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Benzinga - Mentions: LIXT ATRA PPBT MODV ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

6 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

6 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

6 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

6 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

6 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)